JP7516369B2 - トランスサイトーシスのための送達構築物および関連する方法 - Google Patents

トランスサイトーシスのための送達構築物および関連する方法 Download PDF

Info

Publication number
JP7516369B2
JP7516369B2 JP2021525169A JP2021525169A JP7516369B2 JP 7516369 B2 JP7516369 B2 JP 7516369B2 JP 2021525169 A JP2021525169 A JP 2021525169A JP 2021525169 A JP2021525169 A JP 2021525169A JP 7516369 B2 JP7516369 B2 JP 7516369B2
Authority
JP
Japan
Prior art keywords
seq
delivery construct
amino acid
acid sequence
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021525169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506990A5 (cg-RX-API-DMAC7.html
JP2022506990A (ja
Inventor
アミール ポラット,
エルバート セト,
チャールズ オルソン,
ランドル ジェイ. マースニー,
タヒール マームード,
ウェイジュン フェン,
サリー ポストレスウェイト,
Original Assignee
アプライド モレキュラー トランスポート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2019/021474 external-priority patent/WO2019173787A1/en
Priority claimed from PCT/US2019/050708 external-priority patent/WO2020096695A1/en
Application filed by アプライド モレキュラー トランスポート インコーポレイテッド filed Critical アプライド モレキュラー トランスポート インコーポレイテッド
Publication of JP2022506990A publication Critical patent/JP2022506990A/ja
Publication of JP2022506990A5 publication Critical patent/JP2022506990A5/ja
Priority to JP2024107251A priority Critical patent/JP2024127939A/ja
Application granted granted Critical
Publication of JP7516369B2 publication Critical patent/JP7516369B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021525169A 2018-11-07 2019-11-07 トランスサイトーシスのための送達構築物および関連する方法 Active JP7516369B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024107251A JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862756889P 2018-11-07 2018-11-07
US62/756,889 2018-11-07
PCT/US2019/021474 WO2019173787A1 (en) 2018-03-08 2019-03-08 Toxin-derived delivery constructs for oral delivery
USPCT/US2019/021474 2019-03-08
US201962888133P 2019-08-16 2019-08-16
US201962888238P 2019-08-16 2019-08-16
US62/888,133 2019-08-16
US62/888,238 2019-08-16
PCT/US2019/050708 WO2020096695A1 (en) 2018-11-07 2019-09-11 Cholix-derived carriers for oral delivery of heterologous payload
USPCT/US2019/050708 2019-09-11
PCT/US2019/060356 WO2020097394A1 (en) 2018-11-07 2019-11-07 Delivery constructs for transcytosis and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024107251A Division JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Publications (3)

Publication Number Publication Date
JP2022506990A JP2022506990A (ja) 2022-01-17
JP2022506990A5 JP2022506990A5 (cg-RX-API-DMAC7.html) 2022-11-01
JP7516369B2 true JP7516369B2 (ja) 2024-07-16

Family

ID=70612266

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525169A Active JP7516369B2 (ja) 2018-11-07 2019-11-07 トランスサイトーシスのための送達構築物および関連する方法
JP2024107251A Pending JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024107251A Pending JP2024127939A (ja) 2018-11-07 2024-07-03 トランスサイトーシスのための送達構築物および関連する方法

Country Status (21)

Country Link
US (4) US20200140511A1 (cg-RX-API-DMAC7.html)
EP (2) EP4083058A3 (cg-RX-API-DMAC7.html)
JP (2) JP7516369B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210110294A (cg-RX-API-DMAC7.html)
CN (1) CN113423722A (cg-RX-API-DMAC7.html)
AU (1) AU2019377117B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009003A2 (cg-RX-API-DMAC7.html)
CA (1) CA3119060A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001209A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007402A2 (cg-RX-API-DMAC7.html)
CY (1) CY1125216T1 (cg-RX-API-DMAC7.html)
DK (1) DK3650037T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191280A1 (cg-RX-API-DMAC7.html)
ES (1) ES2911075T3 (cg-RX-API-DMAC7.html)
IL (1) IL282987B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005346A (cg-RX-API-DMAC7.html)
PL (1) PL3650037T3 (cg-RX-API-DMAC7.html)
PT (1) PT3650037T (cg-RX-API-DMAC7.html)
SG (1) SG11202104721RA (cg-RX-API-DMAC7.html)
TW (1) TW202031678A (cg-RX-API-DMAC7.html)
WO (1) WO2020097394A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
US20240050559A1 (en) * 2020-06-09 2024-02-15 Icosavax, Inc. Method of making virus-like particle
WO2022177644A1 (en) * 2021-02-16 2022-08-25 Applied Molecular Transport Inc. Methods for treating spondyloarthropathies and related compositions
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
JP2010534061A (ja) 2007-07-20 2010-11-04 ザ ジェネラル ホスピタル コーポレイション 組換えコレラ菌外毒素
JP2013541523A (ja) 2010-09-15 2013-11-14 マースニー,ランドル,ジェイ 細菌毒素由来輸送配列を使用する生物活性剤の送達の系および方法
JP2017519039A (ja) 2014-05-07 2017-07-13 アプライド モルキュラー トランスポート リミテッド ライアビリティー カンパニーApplied Molecular Transport Llc 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US6051405A (en) 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
DE60136281D1 (de) * 2000-08-24 2008-12-04 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
ATE442858T1 (de) 2000-11-27 2009-10-15 Powderject Vaccines Inc Nukleinsäureadjuvantien
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
KR20060022289A (ko) * 2003-06-23 2006-03-09 제네틱스 인스티튜트, 엘엘씨 인터류킨-22 에 대한 항체 및 그의 용도
EP1522585A1 (en) 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
WO2006135428A2 (en) 2004-10-04 2006-12-21 Trinity Biosystems, Inc. Methods and compositions for inducing an immune response against multiple antigens
US7713737B2 (en) 2004-10-04 2010-05-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US20090148401A1 (en) 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US20090092660A1 (en) 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
CA2669094A1 (en) 2006-11-08 2008-05-29 Novavax,Inc. Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 白介素-22在治疗脂肪肝中的应用
US20110250199A1 (en) 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
SG176963A1 (en) * 2009-06-22 2012-02-28 Amgen Inc Refolding proteins using a chemically controlled redox state
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
WO2012101235A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
ES2773115T3 (es) 2011-06-29 2020-07-09 Rani Therapeutics Llc Preparados de agentes terapéuticos para la administración hacia el interior de una luz del tubo intestinal utilizando un dispositivo tragable para la administración de fármacos
PL2970422T3 (pl) 2013-03-15 2018-09-28 F.Hoffmann-La Roche Ag Polipeptydy IL-22 i białka fuzyjne IL-22 Fc i sposoby zastosowania
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
AU2014346554B2 (en) 2013-11-07 2020-06-04 Evive Biotechnology (Shanghai) Ltd Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイSanofi インスリンアナログおよび/またはインスリン誘導体の安定化された医薬製剤
AU2015336101A1 (en) 2014-10-22 2017-04-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107108712A (zh) * 2014-12-23 2017-08-29 阿尔莫生物科技股份有限公司 提高重组蛋白产量的方法
EP3192805A1 (en) 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
CA3045310A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
CA3093386A1 (en) * 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
ES2911075T3 (es) 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
JP2010534061A (ja) 2007-07-20 2010-11-04 ザ ジェネラル ホスピタル コーポレイション 組換えコレラ菌外毒素
JP2013541523A (ja) 2010-09-15 2013-11-14 マースニー,ランドル,ジェイ 細菌毒素由来輸送配列を使用する生物活性剤の送達の系および方法
JP2017519039A (ja) 2014-05-07 2017-07-13 アプライド モルキュラー トランスポート リミテッド ライアビリティー カンパニーApplied Molecular Transport Llc 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子

Also Published As

Publication number Publication date
US20210338828A1 (en) 2021-11-04
EP3650037A1 (en) 2020-05-13
AU2019377117A1 (en) 2021-06-10
EA202191280A1 (ru) 2021-12-27
CA3119060A1 (en) 2020-05-14
IL282987B (en) 2022-10-01
EP3650037B1 (en) 2022-03-02
US20240238429A1 (en) 2024-07-18
CN113423722A (zh) 2021-09-21
BR112021009003A2 (pt) 2021-08-17
PT3650037T (pt) 2022-06-27
KR20210110294A (ko) 2021-09-07
MX2021005346A (es) 2021-10-13
TW202031678A (zh) 2020-09-01
CO2021007402A2 (es) 2021-09-30
US20200140511A1 (en) 2020-05-07
JP2024127939A (ja) 2024-09-20
SG11202104721RA (en) 2021-06-29
AU2019377117B2 (en) 2025-05-29
PL3650037T3 (pl) 2022-06-06
US11027020B2 (en) 2021-06-08
EP4083058A3 (en) 2023-01-11
WO2020097394A1 (en) 2020-05-14
JP2022506990A (ja) 2022-01-17
ES2911075T3 (es) 2022-05-17
EP4083058A2 (en) 2022-11-02
US20200306383A1 (en) 2020-10-01
CY1125216T1 (el) 2024-12-13
DK3650037T3 (da) 2022-05-02
CL2021001209A1 (es) 2021-11-19
IL282987B2 (en) 2023-02-01
IL282987A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP2024127939A (ja) トランスサイトーシスのための送達構築物および関連する方法
US20250388641A1 (en) Novel interleukin-15 (il-15) fusion proteins and uses thereof
JP5876034B2 (ja) Pcsk9に結合するフィブロネクチンベースのスカフォールドドメインタンパク質
Seo et al. Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins
MX2012009050A (es) Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23).
CN108350054A (zh) 双功能蛋白质和包含其的药物组合物
JP2022506990A5 (cg-RX-API-DMAC7.html)
CN110121355A (zh) 用于预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
CN117298254A (zh) 用于口服递送生物活性货物的cholix毒素衍生的融合分子
IL305625A (en) Stable formulations of proteins based on the scaffolding region of fibronectin that bind to myostatin
JP2015512902A (ja) 経口投与
CN111601815A (zh) 靶向细胞中c-Myc的嵌合分子
JP2023512337A (ja) インターロイキン-12とフィブロネクチンのエクストラドメインbに結合する抗体とを含む組換えタンパク質を含む組成物の投与単位およびレジメン、使用、方法または製剤
EA043603B1 (ru) Конструкции для доставки для трансцитоза и связанные способы
ES2728446T3 (es) Proteínas de fusión de P-anticuerpos de amiloide sérico
HK40029390A (en) Delivery constructs for transcytosis and related methods
HK40029390B (en) Delivery constructs for transcytosis and related methods
Wang et al. Rational and efficient preparation of a chimeric protein containing a tandem dimer of thrombopoietin mimetic peptide fused to human growth hormone in Escherichia coli
Zhang et al. Extending the in vivo Half-Life of Adalimumab Fab via Sortase A-Mediated Conjugation of Adalimumab Fab with Modified Fatty Acids
WO2023237935A2 (en) Methods for treating acute conditions using lipid binding protein-based complexes
HK40091844A (en) Dual function proteins and pharmaceutical composition comprising same
WO2024193713A1 (zh) 一种二价il-17治疗性疫苗及其制备方法和应用
HK40086042A (en) Dual function proteins and pharmaceutical composition comprising same
HK40101761A (en) A super-trail molecule comprising two trail trimers
JP2020033372A (ja) 経口投与

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240703

R150 Certificate of patent or registration of utility model

Ref document number: 7516369

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150